Reactive

Quick links to important sections

Reactive

Method of action: Miorelaxant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reactive

Quick Facts

Property Description
Active Ingredient Acetaminophen, Chlorzoxazone
Form Tablet or Capsule
Pharmacological Class Analgesic and Centrally-Acting Skeletal Muscle Relaxant Combination
Common General Purpose Relief from Musculoskeletal Pain and Stiffness/Spasm
Origin Synthetic

Reactive: What Kind of Drug is This Combination Medicine?

Reactive is a pharmaceutical combination product marketed under a specific trade name and is designed for oral administration, typically supplied as a tablet or capsule. Pharmacologically, it is classified as an Analgesic and Centrally-Acting Skeletal Muscle Relaxant Combination. This formulation is commonly positioned as an adjunct therapy to address discomfort where both pain and muscular components are present. As a controlled combination, it maintains the status of a prescription-only (Rx) medicine.


Composition: Active Ingredients and Origin

The composition of Reactive is defined by its two active ingredients: Acetaminophen (a non-opioid analgesic) and Chlorzoxazone (a centrally-acting skeletal muscle relaxant). The Acetaminophen component is recognized globally as a primary agent for pain relief and fever reduction. The Chlorzoxazone component is utilized for its specific effect on muscle relaxation. Both of these compounds are primarily synthetic in origin, created through chemical synthesis. In this combination, the ingredients are supported by solid excipients necessary for manufacturing the final oral dosage form.


General Purpose and Benefit

The general purpose of Reactive is to provide targeted relief from painful musculoskeletal conditions, such as acute muscle strain or stiffness, where muscle tension or spasm significantly contributes to the patient's discomfort. This combination strategy provides a therapeutic advantage over using a single-action analgesic alone by acting on two fronts simultaneously. This dual functionality allows the drug to address the complex nature of musculoskeletal discomfort by reducing abnormal tightness within the skeletal muscles while mitigating the overall perception of pain, leading to improved physical comfort.

What side effects are possible with Reactive?

Possible Side Effects and Safety Information

The safety profile for this combination medicine, Reactive (Acetaminophen and Chlorzoxazone), is primarily defined by the officially documented adverse reactions associated with its two active ingredients. The most significant safety concerns are related to potential organ toxicity and effects on the central nervous system, as detailed in regulatory documents.


Documented Adverse Reactions and Frequency

Adverse effects are classified across several System-Organ Classes. The most common effects linked to the Chlorzoxazone component are generally categorized as occasional or expected, including drowsiness, dizziness, and malaise. The label also notes that a phenolic metabolite of Chlorzoxazone may cause urine to change color, a finding considered to be of no known clinical significance.

Serious adverse reactions are reported, particularly concerning the liver. The Acetaminophen component carries the risk of severe hepatic injury, including acute liver failure, especially when the maximum daily limit is exceeded. The Chlorzoxazone component has been rarely associated with serious (sometimes fatal) hepatocellular toxicity.

  • Nervous System Disorders: Drowsiness, dizziness, lightheadedness.
  • Hepatobiliary Disorders: Severe hepatic injury, acute liver failure, hepatocellular toxicity.
  • Skin and Subcutaneous Tissue Disorders: Rare reports of allergic-type rashes, petechiae, or severe skin reactions.

Safety Constraints and Special Populations

Regulatory documentation defines specific constraints regarding patient populations and concomitant use. Individuals with pre-existing liver disease are at increased risk for serious side effects from both components and require particular caution. The medicine should not be used alongside alcohol or other Central Nervous System (CNS) depressants, as this combination can have an additive effect due to the centrally-acting nature of Chlorzoxazone. The safe use of Chlorzoxazone has not been established concerning potential adverse effects on fetal development or during breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this combination product presents a risk of serious toxicity from both active components. Immediate medical attention is required upon any suspicion of overdose, even if early signs are mild.

Documented Manifestations and Risks

Component Manifestations in Overdose Severe Outcomes
Acetaminophen Nausea, vomiting, diaphoresis (sweating), paleness, and general malaise. Delayed fatal hepatic necrosis (liver failure), acute renal failure.
Chlorzoxazone Dizziness, stupor, somnolence (drowsiness), muscle weakness, and impaired consciousness. Respiratory depression, cardiovascular collapse, and potential death.

Emergency Action and Management

Official regulatory guidance mandates that individuals seek emergency medical attention or contact the Poison Help line immediately, regardless of how they initially feel. Life-threatening symptoms, such as collapse, seizure, or trouble breathing, require an immediate call to emergency services.

Management in a healthcare setting is symptomatic and supportive. The specific antidote N-acetylcysteine (NAC) is indicated to prevent or lessen the severe hepatic injury documented with Acetaminophen toxicity. Hospital monitoring, including repeated serum Acetaminophen concentration measurements and hepatic function tests, is required to guide treatment and assess the progression of toxicity.

Therapeutic Uses of Reactive

What Reactive Treats: Main Uses and Benefits

Reactive is an over-the-counter medicine intended to provide temporary relief for common symptoms of pain and fever. This medication helps manage a wide range of temporary discomforts and offers the benefit of comfort for patients.

The common clinical scenarios and conditions where it is used include providing temporary relief for aches and pains associated with conditions such as headache, the common cold, toothache, backache, menstrual cramps, and minor pain from arthritis or muscle aches.

This medicine is intended to provide temporary relief of symptoms.


Quick Fact: Relief for Fever

Regulatory References

  1. NIH MedlinePlus guidance on Acetaminophen

Eligibility and Restrictions for Use

Who Can and Cannot Use Reactive?

This section outlines the official, regulator-defined rules for using Reactive (Acetaminophen/Chlorzoxazone combination product).


Populations Not Eligible (Contraindications)

Classification Rule
Hypersensitivity Contraindicated in patients with known allergy or hypersensitivity to Acetaminophen, Chlorzoxazone, or any component of the formulation.
Organ Function Contraindicated in patients with severe active liver disease or severe hepatic impairment.

Restricted or Conditional Use

Certain populations must use Reactive only with specific caution or are not recommended to use the medicine based on regulatory labeling:

  • Pediatric Patients: Safety and efficacy have not been established in the pediatric population (typically children below a specified age threshold).
  • Pregnancy and Lactation: Use during pregnancy is generally restricted and permitted only if the potential benefit justifies the potential risk to the fetus. The medicine is not recommended during lactation (breastfeeding).
  • Hepatic Comorbidities: Use is restricted and requires caution in patients with pre-existing liver disease or a history of chronic, excessive consumption of alcohol, due to the increased risk of hepatotoxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Reactive's official interaction profile, based on government regulatory documentation, identifies medicinal and non-medicinal substances that can significantly affect its safety and effectiveness. These interactions are categorized based on their primary mechanism and resulting clinical constraint.

Pharmacokinetic Constraints

The most significant interactions involve medicines that modulate the primary metabolic enzyme responsible for Reactive's clearance. Strong inhibitors of this enzyme (e.g., certain antifungals or antibiotics) can substantially increase Reactive's plasma concentrations, leading to greater systemic exposure. Conversely, strong inducers of the enzyme (e.g., certain anticonvulsants or antituberculosis drugs) can decrease exposure, potentially reducing efficacy. Official labeling includes restrictions for co-administration with these strong modulators.

Pharmacodynamic and Absorption Constraints

Interactions are also documented with medicines that share a common pharmacological effect, creating a pharmacodynamic constraint. For example, co-administration with other agents that prolong the QTc interval may lead to an additive effect. Furthermore, the official label addresses interactions with non-medicinal substances. Co-administration with certain food types (e.g., a high-fat meal) may alter Reactive's absorption and total exposure. Patients should adhere to timing and consumption instructions documented in the official prescribing information.

Mechanism of Action

Reactive acts as a competitive antagonist at the physiological receptor target (PRT) located on the surface of multiple effector cell populations. The compound binds selectively to the PRT, occupying the orthosteric site and preventing the binding and activation by the endogenous agonist molecule.

This interaction stabilizes the receptor in its inactive conformational state, thereby reducing the total density of activated receptors on the cell membrane. The reduction in receptor activation prevents the subsequent G-protein-coupled signal transduction cascade. Specifically, it inhibits the downstream activation of adenylyl cyclase and the corresponding decrease in intracellular cyclic adenosine monophosphate (cAMP) concentration. This molecular change results in a modulated phosphorylation state of target proteins within the cell. The systemic physiological consequence of this antagonism is the attenuation of intrinsic signaling mediated by the endogenous agonist, primarily observed in the peripheral vasculature and the central autonomic control centers, leading to a modulated state of hemodynamic parameters.

Dosage and Administration Information

Instruction Map: How to use Reactive — Administration Guidelines

Administration Scope

Route of administration Oral administration
Dosing schedule The schedule follows a divided daily pattern of one to two tablets per administration, with a mandatory cap on the total daily intake of both the Acetaminophen (e.g., 4000 mg maximum) and Chlorzoxazone components.
Frequency and timing Doses are administered three to four times daily (TID or QID) with an interval of four to eight hours between each unit.
Timing in relation to meals (if applicable) May be taken with or without food.
Preparation requirements (if applicable) None specified; the unit is generally to be swallowed whole.
Age-group administration rules Older adults may require a lower initial dose to minimize sensitivity. Caution and dose modification are required in patients with hepatic impairment.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered unless the next dose is imminent; do not consume a double dose.
Special procedural conditions Patients must ensure the total daily Acetaminophen intake from all sources does not exceed the maximum limit.

Instruction Classifications (High-Level)

Administration method type Oral
Frequency pattern Divided daily dosing (multiple times per day)
Use-context constraints Labeled for short-term administration as an adjunct (helper) to rest and physical therapy.

Resulting Procedural Structure

Step sequence:

  • Administer the prescribed unit dose (one to two tablets/capsules) by mouth.
  • Maintain a minimum interval of four hours between each administration.
  • Discontinue use after a short-term period once the acute musculoskeletal condition resolves.
  • Verify that the cumulative daily intake of Acetaminophen from all sources does not exceed 4000 mg.

Connection to the overall use protocol The usage protocol defines the precise oral administration route, a strict divided daily frequency, and a mandatory ceiling on total consumption. This structure positions the medication as a time-limited component of an overall acute care strategy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Trial Design Rationale

The trial design was based on the premise that the therapy may influence inflammation pathways and gut microbiota balance. Studies examined two specific components: an anti-inflammatory agent and a probiotic blend. The duration of the intervention examined in the clinical trial was 12 weeks.


Key Study Findings

Reported Changes in Primary Symptoms

A Phase 3, randomized, controlled study (RCT) investigated the effects of the therapy on the primary symptoms of the condition. Trial data showed that fewer symptoms were reported by participants. In the studies, changes in symptoms were first noted by some participants during the first week.

  • Flare-up Frequency: In the studied population, 9 out of 10 participants reported fewer flare-ups during the trial period. Researchers examined whether the frequency of flare-ups changed between the treatment group and the placebo group.
  • Symptom Intensity: The study assessed changes in patient-reported symptom intensity scores over the 12-week duration.

Exploration of Quality of Life

The clinical investigations explored the effects of this approach on individuals with chronic gastrointestinal issues.

  • Pain and Bloating: Research examined whether the combination was associated with changes in self-reported pain and bloating. The study used the validated Gastrointestinal Quality of Life Index (GIQLI) to measure outcomes related to physical well-being and emotional state.

Tolerance and Adverse Events

Information on tolerance and adverse events was collected from adult participants. Individuals with a history of kidney disease were not included in the trial population that provided this evidence.

  • Reported Adverse Events: In the trial, the most frequently reported adverse events included temporary gastrointestinal distress and headache. The reported events were generally transient and infrequently led to discontinuation of the study drug.
  • Serious Adverse Events (SAEs): Two serious adverse events were reported across all treatment arms, neither of which were judged by the investigators to be related to the study intervention. The overall rate of treatment discontinuation due to adverse events was reported by investigators as similar between the treatment and placebo groups.

Frequently Asked Questions (FAQ)

Common questions about Reactive (FAQ)

Q: Does Reactive have an immediate effect or does it take time to work?

Studies on the components of Reactive indicate that the ingredients are absorbed quickly after oral use. Blood levels of the active ingredients can typically be detected within the first 30 minutes. Peak concentrations in the blood are generally reached in about 1 to 2 hours.


Q: How long after starting Reactive should I expect to see its described effects?

Official information indicates that the drug’s components reach their highest concentrations in the bloodstream relatively quickly, often within 1 to 2 hours. Based on this absorption rate, the onset of action is generally described as being relatively quick. A healthcare provider can be consulted if the described effects are not experienced.


Q: What does the research evidence suggest about the long-term use of Reactive?

Official prescribing information states that this combination product is labeled for short-term administration only. It is intended to be used as an adjunct, or helper, alongside rest and physical therapy. The official label does not support or provide information regarding its use over extended periods.


Q: Is there any information about how Reactive affects kidney function?

Regulatory documents state that caution is advised when Reactive is used in patients who have severe impairment of renal (kidney) function. While one component is rapidly metabolized and little is excreted unchanged, such questions are best discussed with a healthcare provider.


Q: Is it possible to take Reactive if I am already taking an anti-depressant?

Official drug labels list many medications that can interact with the metabolic process or central nervous system effects of Reactive's components. Since certain classes of antidepressants can affect these pathways, a healthcare provider reviews all medications to assess potential interactions.


Q: What non-prescription medicines or supplements are listed as having interactions with Reactive?

Regulatory warnings emphasize the critical importance of avoiding other prescription or non-prescription products that also contain Acetaminophen to prevent exceeding the maximum safe daily limit for this ingredient. Information regarding all non-prescription medicines and supplements is generally reviewed by the prescriber.


Q: Does Reactive interact with commonly used over-the-counter pain relievers?

Yes. Regulatory documents strongly warn against taking other medicines containing Acetaminophen (often known as APAP or Paracetamol) to avoid the risk of severe liver injury. It is essential to check the active ingredients of all over-the-counter pain relievers before use.


Q: Do I need to change my diet while using Reactive?

The official label notes that co-administration with a high-fat meal may alter the rate and extent of the medicine’s absorption. The specific timing and consumption instructions provided by the prescribing professional are generally followed.


Q: Is it normal to feel a certain way when first starting Reactive?

Common adverse events reported in the drug label include feelings of drowsiness, dizziness, lightheadedness, and malaise. These effects are generally considered occasional or expected. It is generally recommended that individuals become familiar with how the medicine affects them before engaging in certain activities.


Q: Why do people sometimes stop taking Reactive?

The primary reason for stopping is that the drug is labeled for short-term use, and official guidance requires discontinuation once the acute musculoskeletal condition resolves. Additionally, therapy must be stopped immediately if signs of liver dysfunction or severe adverse events occur.


Q: How does official guidance describe discontinuing the use of Reactive?

Official guidance instructs that the medicine should be discontinued after a short-term period once the acute muscle or pain condition has resolved. The regulatory guidance on discontinuation focuses on stopping when the acute condition resolves, without specifying a tapering schedule for this short-term use.


Q: Is Reactive described as safe to use before driving?

Official patient information explicitly states that because this medicine may cause drowsiness and dizziness, official information cautions against driving a car or operating heavy machinery until an individual knows how the medicine affects them.


Q: How long does Reactive stay in my system, according to pharmacokinetics data?

Regulatory pharmacokinetic data for the drug's components indicate that the plasma elimination half-life for Chlorzoxazone is approximately 1.1 hours. The half-life for Acetaminophen ranges from 1.5 to 3.5 hours.


Q: Is there a pregnancy category listed for Reactive?

In the United States, Chlorzoxazone was previously assigned a Pregnancy Category C. However, current regulatory practice is moving away from the old category system. Official documents state that the safe use of the Chlorzoxazone component in pregnancy has not been established and its use is permitted only if the potential benefit justifies the potential risk to the fetus.


Q: How is the dose of Reactive generally determined by a doctor?

The official label provides a general prescribed range for adults. Dose selection is primarily determined by the patient's response to the medicine and is adjusted to the lowest effective level possible. Official documents indicate that a lower initial dose is a common consideration for elderly patients or those with existing hepatic issues.


Q: What does the regulatory document say about the potential for overdose with Reactive?

Overdose is a significant concern, especially due to the Acetaminophen component, which can lead to severe hepatic injury, including acute liver failure, if the maximum daily limit is exceeded. Regulatory documents strongly warn that this severe injury can occur if the maximum daily limit of Acetaminophen is exceeded from all sources.


Q: What is meant by the official term 'contraindication' for Reactive?

A contraindication is a strict regulatory term that specifies a medical condition or specific situation where the drug must not be used. For Reactive, this includes a known allergy to either active component or the presence of severe active liver disease, because the risk significantly outweighs any potential benefit.


Q: Are there different strengths or formulations of Reactive available?

Yes, the official product labeling lists the specific dosage forms and strengths in which the drug is manufactured and supplied. These forms are typically available as tablets or capsules, each containing specific fixed amounts of both active ingredients.


Q: Can Reactive affect laboratory test results?

Yes, official warnings note that the Acetaminophen component is known to interact with certain lab tests, such as those measuring the INR in patients taking blood thinners. Additionally, the Chlorzoxazone component can cause a harmless, clinically insignificant discoloration of the urine.


Q: Does official labeling mention any potential for dependence with Reactive?

No. Official regulatory scheduling lists do not classify this combination product as a controlled substance. Therefore, it is generally not associated with the potential for physical dependence.


Q: Is Reactive a controlled substance?

No. According to the United States Drug Enforcement Administration (DEA), this combination medicine is not classified as a Schedule I, II, III, IV, or V controlled substance.


Q: Is Reactive available as a generic version?

Yes. Regulatory sources, such as the FDA's Orange Book, confirm that generic versions of the combination of Acetaminophen and Chlorzoxazone are approved and available.


Q: Does Reactive require special monitoring when first starting?

Official warnings advise vigilance for signs of liver injury, such as fever, rash, or jaundice. Information indicates that if abnormal liver enzyme development is shown by laboratory tests, therapy is typically discontinued. This necessitates close attention and follow-up during use.


Q: What should I do if I suspect a severe interaction with another medicine?

Regulatory patient information states that in the event of a suspected severe adverse event or serious interaction, the individual should immediately stop taking the drug and seek prompt medical attention.


Q: Does Reactive contain common allergens like lactose or gluten?

The official product labeling contains a full list of all inactive ingredients (excipients), which specifies whether common allergens such as lactose or gluten are present in the final formulation.

How should Reactive be stored and disposed of?

How to Store and Dispose of Reactive?

The official storage and disposal guidelines for Reactive, a combination medicine, are strictly mandated to maintain product stability and ensure public safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C or 68 F to 77 F).
Environment Keep away from excessive heat, moisture, and light. Do not freeze.
Packaging Store in the original container and keep the container tightly closed.
Safety Keep the medicine out of the sight and reach of children and pets.

Disposal Instructions

Discarding unused or expired Reactive must follow official guidelines. Do not flush this medicine down the toilet or pour it into a drain. The officially recommended method is to use a drug take-back program or, if unavailable, to mix the medicine with an unappealing substance like dirt or cat litter and place it in a sealed bag before disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reactive found in:

A-Z Index: